Generic
Mumps, Rubella, Measles (Live Attenuated) Vaccine
2 brands available in the market
At a glance
Mumps, Rubella, Measles (Live Attenuated) Vaccine is a live attenuated virus vaccine that provides active immunity against measles, mumps and rubella infections. It is indicated for both children and adults.
Description
Live, attenuated viruses stimulate active immunity to disease caused by measles, rubella, and mumps viruses. The vaccine is administered as 0.5 mL SC.
Indications
- Active immunization against infection by measles, mumps and rubella
- Routine vaccination of children (12-15 months and 4-6 years)
- Vaccination of adults (19-49 years)
- Rubella immunization in non-pregnant women
- International travelers and healthcare workers
Therapeutic class
Vaccines
Pharmacological class
Live Attenuated Virus Vaccine
Pharmacology
Live, attenuated viruses stimulate active immunity to disease caused by measles, rubella, and mumps viruses.
Mechanism of action
Provides immunity against measles, mumps and rubella viruses.
Dosage
Pediatric Dose (IM/SC):
- 12-15 months: 0.5 mL SC (1st dose)
- 4-6 years: 0.5 mL SC (2nd dose)
- Minimum time between 1st and 2nd dose: 4 weeks
Adult Dose (IM/SC):
- 19-49 years: 0.5 mL SC; second dose may be given 28 days apart
- >50 years: 0.5 mL SC (1 dose only)
Immunization in Pregnancy: Give MMR vaccine after pregnancy completion; avoid pregnancy for 28 days after vaccination
Administration
- Administered as subcutaneous (SC) injection
- Given by doctor or nurse
Missed dose
Not generally applicable (scheduled administration); consult doctor if needed.
Side effects
Common Side Effects:
- Fever
- Headache
- Rash
- Pain at injection site
- Lymphadenopathy
- Myalgia
- Malaise, irritability
Rare: Ataxia, Thrombocytopenia, Optic neuritis, Encephalitis, Guillain-Barre syndrome, Seizures, Parotitis, Bronchospasm, Stevens-Johnson syndrome, Nerve deafness
Precautions & warnings
- Caution in patients with history of cerebral injury or seizures
- Caution in patients with thrombocytopenia and those who develop thrombocytopenia after 1st dose
- Tuberculosis treatment should be started before vaccine use in active TB patients
- Vaccination may be deferred in moderate or severe acute illness
- Avoid pregnancy for 28 days after vaccination
Contraindications
- Current febrile respiratory illness or other febrile infection
- Patients receiving immunosuppressive therapy
- Primary and acquired immunodeficiency states
- Blood dyscrasias, cancers affecting bone marrow or lymphatic systems
- Pregnancy
- Active untreated tuberculosis
Drug interactions
- Immune globulins may reduce vaccine efficacy
- May reduce diagnostic effect of tuberculin tests
- Concurrent use with immunosuppressants may increase adverse effects and reduce efficacy
Food interactions
No food interactions.
Use in pregnancy
Use in Pregnancy: Contraindicated in pregnancy. Avoid pregnancy for 28 days after vaccination. May be given after pregnancy completion.
Pregnancy Category: C — always consult a doctor before taking during pregnancy.
Use in lactation
Use in Lactation: Rubella is excreted in milk; use caution.
Pediatric use
Indicated for children aged 12-15 months and 4-6 years.
Geriatric use
Doses established for adults aged 19-49 years and >50 years.
Renal / hepatic impairment
Renal Impairment: Caution in kidney disease; consult doctor.
Hepatic Impairment: Caution in liver disease; consult doctor.
Overdose effects
Limited information on overdose; symptomatic treatment.
Storage conditions
Store at 2-8°C; protect from light; do not freeze; keep out of reach of children.
Chemical structure
MMR Vaccine